Caribou Biosciences, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Caribou Biosciences, Inc. (CRBU) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$574.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13
- Caribou Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$52.00K.
- Caribou Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$522.00K.
- Caribou Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$2.40M, a 48160.00% decline year-over-year.
- Caribou Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$461.00K, a 273.31% decline year-over-year.
- Caribou Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$3.67M, a 948.73% decline from fiscal 2024.
- Caribou Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $433.00K.
- Caribou Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$1.77M, a 281.13% decline from fiscal 2022.
- Caribou Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $975.00K, a 75.88% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$574.00K 10-Q · filed 2026-08-13 | -$2.98M derived: sum of 3 quarters · filed 2026-08-13 | -$3.44M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$522.00K 10-Q · filed 2026-05-07 | -$2.92M derived: sum of 2 quarters · filed 2026-05-07 | -$3.39M derived: sum of 3 quarters · filed 2026-05-07 | -$3.73M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$2.86M derived: sum of 2 quarters · filed 2026-03-05 | -$3.20M derived: sum of 3 quarters · filed 2026-08-13 | -$3.67M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$461.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$801.00K derived: sum of 2 quarters · filed 2026-08-13 | -$1.27M 10-Q · filed 2025-11-12 | -$1.27M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$340.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$811.00K 10-Q · filed 2026-08-13 | -$806.00K derived: sum of 3 quarters · filed 2026-08-13 | -$540.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$471.00K 10-Q · filed 2026-05-07 | -$466.00K derived: sum of 2 quarters · filed 2026-05-07 | -$200.00K derived: sum of 3 quarters · filed 2026-05-07 | -$796.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $271.00K derived: sum of 2 quarters · filed 2026-03-05 | -$325.00K derived: sum of 3 quarters · filed 2026-03-05 | $433.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $266.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$330.00K derived: sum of 2 quarters · filed 2025-11-12 | $428.00K 10-Q · filed 2025-11-12 | -$486.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$596.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $162.00K 10-Q · filed 2025-08-12 | -$752.00K derived: sum of 3 quarters · filed 2025-08-12 | $752.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $758.00K 10-Q · filed 2025-05-08 | -$156.00K derived: sum of 2 quarters · filed 2025-05-08 | $1.35M derived: sum of 3 quarters · filed 2025-05-08 | $803.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$914.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $590.00K derived: sum of 2 quarters · filed 2025-03-10 | $45.00K derived: sum of 3 quarters · filed 2025-03-10 | -$1.77M 10-K · filed 2025-03-10 |
| 2023-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $959.00K derived: sum of 2 quarters · filed 2024-11-06 | -$852.00K 10-Q · filed 2024-11-06 | -$1.49M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$545.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$2.36M 10-Q · filed 2024-08-06 | -$2.99M derived: sum of 3 quarters · filed 2024-08-06 | -$1.73M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$1.81M 10-Q · filed 2024-05-07 | -$2.45M derived: sum of 2 quarters · filed 2024-05-07 | -$1.18M derived: sum of 3 quarters · filed 2024-05-07 | -$2.13M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$638.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $628.00K derived: sum of 2 quarters · filed 2024-03-11 | -$321.00K derived: sum of 3 quarters · filed 2024-03-11 | $975.00K 10-K · filed 2024-03-11 |
| 2022-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $317.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.61M 10-Q · filed 2023-11-07 | $2.90M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$949.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $347.00K 10-Q · filed 2023-08-08 | $1.63M derived: sum of 3 quarters · filed 2023-08-08 | $2.55M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $1.30M 10-Q · filed 2023-05-09 | $2.58M derived: sum of 2 quarters · filed 2023-05-09 | $3.50M derived: sum of 3 quarters · filed 2023-05-09 | $4.78M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $2.20M derived: sum of 2 quarters · filed 2023-03-09 | $3.48M derived: sum of 3 quarters · filed 2023-03-09 | $4.04M 10-K · filed 2023-03-09 |
| 2021-09-30 | $917.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.20M derived: sum of 2 quarters · filed 2022-11-08 | $2.76M 10-Q · filed 2022-11-08 | $3.88M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.84M 10-Q · filed 2022-08-09 | $2.97M derived: sum of 3 quarters · filed 2022-08-09 | $3.04M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $562.00K 10-Q · filed 2022-05-09 | $1.69M derived: sum of 2 quarters · filed 2022-05-09 | $1.75M derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $1.19M derived: sum of 2 quarters · filed 2022-03-21 | -$362.00K 10-K · filed 2022-03-21 | |
| 2020-09-30 | $68.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$1.49M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$1.55M 10-Q · filed 2021-09-02 | |||
| 2019-12-31 | $1.35M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |